Publicis


DEAR HEALTH (CONT’D)

20/09/22 -"Over the last three years, AlphaValue has been on a mission to call Health stocks expensive. That segment excludes Pharmas. The sector is down 30%, of which 7% over the last week. That still leaves ..."

Pages
58
Language
English
Published on
20/09/22
You may also be interested by these reports :
04/10/22
Late last week MFE reported its H1 numbers. Like in the Q1, the Q2 operating profit was clearly disappointing. We have to admit that, despite MFE’s ...

04/10/22
Following the H1 release we have revised our numbers sharply lower for 2022 and 2023. Operating costs should increase by 5% in 2022 in Italy while ...

20/09/22
Publicis (Add, France) is the third largest global advertising company in the world (total revenue of $13.9bn in 21) behind no.1 WPP (Add, UK) and ...

19/09/22
The chronology of events raised doubts on the completion of the proposed merger. Nevertheless, the cancellation of the operation before the date of ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO